New studies on retatrutide, a dual activator for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, demonstrate significant outcomes in addressing obesity and type 2 glucose intolerance. Initial data from clinical trials reveal substantial decreases in body mass and enhance